Compare PCYO & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PCYO | SWKH |
|---|---|---|
| Founded | 1976 | 1996 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Water Supply | Diversified Financial Services |
| Sector | Utilities | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.8M | 198.4M |
| IPO Year | 1995 | N/A |
| Metric | PCYO | SWKH |
|---|---|---|
| Price | $10.36 | $16.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 46.9K | 8.0K |
| Earning Date | 04-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,227,787.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.95 | ★ $9.18 |
| Revenue Growth | ★ 171.54 | N/A |
| 52 Week Low | $9.65 | $13.00 |
| 52 Week High | $12.16 | $18.66 |
| Indicator | PCYO | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 48.96 |
| Support Level | $9.84 | $16.65 |
| Resistance Level | $10.62 | $17.08 |
| Average True Range (ATR) | 0.31 | 0.33 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 59.90 | 59.11 |
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.